Letters Universal meningitis vaccination

Cost effectiveness has its place, but so does common sense

BMJ 2014; 349 doi: http://dx.doi.org/10.1136/bmj.g6759 (Published 13 November 2014) Cite this as: BMJ 2014;349:g6759
  1. Rino Rappuoli, global head vaccines research1,
  2. James Wassil, clinical development2,
  3. Lars Bonefeld, market access3,
  4. John Porter, medical director3
  1. 1Novartis Vaccines and Diagnostics, Siena, Italy
  2. 2Novartis Vaccines and Diagnostics, Cambridge, MA, USA
  3. 3Novartis Vaccines and Diagnostics Limited, Frimley, UK
  1. rino.rappuoli{at}novartis.com

Cost effectiveness models are useful tools for equitable rationing of health budgets but should not be the only component of the decision making process. This is particularly true for vaccination of children for rare diseases, where crucial parameters are inherently uncertain. In this case, the uncertainty is evident; Christensen and colleagues’ paper is the third iteration of the model,1 with each leading to different conclusions …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe